BioSpace News Archive

Tiziana Life Sciences is pleased to announce that the U.S. Food and Drug Administration allowed enrollment of a second patient in the ongoing clinical treatment of secondary progressive multiple sclerosis with intranasally administered foralumab, a fully human anti-CD3 monoclonal antibody, at the Brigham and Women’s Hospital, Harvard University, Boston, MA.

Nuvation Bio Inc. provided a corporate update and highlighted key 2022 milestones in anticipation of its presentation at the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10 – 13, 2022.

AtriCure, Inc., a leading innovator in surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2021 and provided 2022 financial guidance.

Deciphera Pharmaceuticals, Inc. today provided a corporate update and highlighted key 2022 milestones.

Epizyme today provided an update on recent business highlights and its outlook for 2022.

Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2021.

Moderna, Inc. today announced recent updates on its industry-leading mRNA pipeline.

Sirolimus, also known by its USAN-assigned generic name rapamycin, has gained traction in the medical and healthcare industries for its outstanding antitumor and immunosuppressive activities.

Sema4 today announced preliminary revenue (unaudited) for the fourth quarter and fiscal year ended December 31, 2021 and provided a business update.

Biological products or biologics refer to medicines manufactured using living organisms. For the manufacturing of these products, highly complex processes are performed under strict observations and controlled conditions.